Diabetes Mellitus: Metformin, Glimepiride, Gliclazide, Sitagliptin, Vildagliptin, and Insulin
Key points Cardiovascular outcome trials in individuals with type 2 diabetes mellitus demonstrate that glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce the rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death
Similar content being viewed by others Subjects Introduction In vivo genome editing using tools like CRISPR-Cas9 have demonstrated great potential for correcting disease-causing mutations and ensuring sustained correction outcome in monogenic inherited diseases 1,2,3,4
if more than 5 days have passed, skip that dose and resume your weekly schedule
I didn't lose weight, but my blood pressure and glucose levels remained normal
NICE guidance provides clear recommendations for GLP-1 use, which focus exclusively on glycaemic control in type 2 diabetes (NG28) and weight management in obesity (TA875 for semaglutide, TA664 for liraglutide)